<DOC>
	<DOCNO>NCT02390934</DOCNO>
	<brief_summary>The purpose Phase II single-arm study evaluate efficacy Radium-223 treat bone lesion differentiate thyroid cancer I-131 refractory . Based result phase III trial , protocol use injection Radium-223 activity 50 kBq/kg b.w . give 6 time 4 week interval apply . The end point study evaluation Radium-223 efficacy one month 3 administration , i.e . 3 month first injection . If disease progression time exclude , patient treat 3 injection total 6 administration Radium-223 . The principal response criterion 3 6 month metabolic response FDG PET/CT , image technique also perform : axial skeleton MRI , 99mTc-HMDP bone scan FNa PET/CT . Axial skeleton MRI reference soft tissue study . 99mTc- HMDP bone scan use available routine tool detect bone metastasis cancer patient , sensitivity patient bone metastasis thyroid cancer low , lesion lytic [ 23 ] . 18FNa PET/CT show high sensitivity 99mTc-HMDP bone scan detect bone lesion cancer patient able detect micrometastases see bone scan [ 24 ] [ 25 ] . Preliminary result show interest use tracer evaluate sclerotic component bone metastases thyroid cancer [ 26 ] . Furthermore preliminary data show FNa PET/CT useful quantify response Radium-223 prostate cancer . In five patient evaluate FNa PET/CT baseline , 6 week 12 week 100 KBq/Kg Radium-223 , semiquantitative analysis SUV max show relationship PSA SUV max level decrease 3 patient ( -44 % , -31 % , -27 % vs -52 % , -75 , -49 % respectively ) [ 27 ] . Finally bone metastasis visible morphological imaging ( CT scan RI ) frequently submit local treatment modality , may induce fibrosis recalcification . Therefore , already treat metastasis treat metastasis study separately two separate subgroup target lesion .</brief_summary>
	<brief_title>Efficacy Radium 223 Radioactive Iodine Refractory Bone Metastases From Differentiated Thyroid Cancer</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Thyroid Diseases</mesh_term>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<criteria>1 . Affiliated social security regimen ; 2 . Patients histologically confirm differentiate thyroid cancer ( papillary , follicular include Hurthle cell poorly differentiate ) ; 3 . Iodine refractory disease define absence radioiodine uptake least one lesion progression disease within 14 month radioactive iodine ( RAI ) treatment persistent disease administration cumulative activity 22GBq I 131 ; 4 . Age ≥18 year ; 5 . Eastern Cooperative Oncology Group performance status 02 ; 6 . Life expectancy longer 3 month ; 7 . Presence least one bone metastasis visible CT scan axial skeleton ( AS ) MRI require urgent locoregional treatment ; 8 . Presence least one bone metastasis uptake FDG PET/CT ; 9 . Presence least one bone metastasis increase uptake 99mTc HMDP bone scintigraphy FNa PET/CT 10 . Low likelihood indication systemic treatment within next 6 month , define absence soft tissue distant metastasis presence small ( &lt; 1cm ) softtissue metastasis , large ( &gt; 1 cm ) stable soft tissue metastasis within 6 month prior inclusion present protocol ; 11 . Adequate haematological ( neutrophils ≥1,5×109/L ; platelet ≥100×109/ L ; haemoglobin &gt; 9g/dL ) , renal ( creatinine &lt; 1,5×upper limit normal range ) , hepatic ( total bilirubin &lt; 1.5 institutional upper limit normal ) , aspartate aminotransferase alanine aminotransferase &lt; 2,5×upper limit normal range absence liver metastases &lt; 5×upper limit normal range case liver metastasis ) function ; 12 . Patients receive bisphosphonates antiRANK ligand ( Denosumab ) allow patient receive least 2 administration prior Radium223 administration treatment continue Radium223 treatment ; 13 . Blood negative pregnancy test woman childbearing potential within 30 day prior treatment initiation . Both men woman ( childbearing potential ) sexually active must use adequate contraception least 6 month posttreatment ; 14 . Patient fully inform , able comply protocol sign informed consent . 1 . Patients another malignancy remission least 2 year ( except situ cervix uterine cancer , basocellular skin cancer ) ; 2 . Treatment investigational drug TKI within previous 4 week , plan treatment period ; 3 . Treatment cytotoxic chemotherapy within previous 4 week , plan treatment period , failure recover adverse event due cytotoxic chemotherapy administer 4 week study initiation ; 4 . Previous systemic therapy radionuclides , include strontium89 , samarium153 , rhenium186 , rhenium188 radium223 ; 5 . Patients imminent establish spinal cord compression base clinical finding and/or MRI and/or immediate need local radiotherapy ; 6 . Patients progressive visceral metastasis accord RECIST 1.1 criterion assess CT scan and/or symptomatic brain metastasis within 6 month prior study initiation ; 7 . Patient already include clinical trial ; 8 . Pregnant breast feeding woman ; 9 . Fecal urinary unmanageable incontinence ; 10 . Bone marrow dysplasia , uncontrolled diabetes infection , NYHA Class III IV cardiac disorder , fecal incontinence symptomatic intestinal disease ( Crohn disease ulcerative colitis ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Radium 223</keyword>
	<keyword>bone metastasis</keyword>
</DOC>